Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: Involvement of the Fas receptor/ligand system

British Journal of Pharmacology

Volumn 127, Issue 4, 1999, Pages 813-825

  Cabaner, Christelle ^a,b   Gajate, Consuelo ^a,b   Macho, Antonio ^c   Muñoz, Eduardo ^c   Modolell, Manuel ^d   Mollinedo, Faustino ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c Universidad de Cordoba   (Spain)

^d MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

Activated T lymphocytes; Antitumour ether lipids; Apoptosis; Autoimmune disease; Edelfosine; ET 18 OCH3; Fas FasL system; Ilmofosine; Miltefosine; Mitochondrial transmembrane potential

Indexed keywords

CELL DNA; CONCANAVALIN A; DNA FRAGMENT; EDELFOSINE; FAS LIGAND; ILMOFOSINE; INTERLEUKIN 2; MESSENGER RNA; MILTEFOSINE; PHYTOHEMAGGLUTININ; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL CYCLE; CYTOFLUOROMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CYCLOHEXIMIDE; FAS LIGAND PROTEIN; HUMANS; IN SITU NICK-END LABELING; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; MITOCHONDRIA; MITOGENS; PHOSPHOLIPID ETHERS; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES;

EID: 0032981815     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702606     Document Type: Article

References (55)

1. ACHA-ORBEA, H., MITCHELL, D.J., TIMMERMANN, L., WRAITH, D.C., TAUSCH, G.S., WALDOR, M.K., ZAMVIL, S.S., MCDEVITT, H.O. & STEINMAN, L. (1988). Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell, 54, 263-273.
2. AGGARWAL, S. & GUPTA, S. (1998). Increased apoptosis of T cell subsets in aging humans: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J. Immunol. 160, 1627-1637.
3. ANDREESEN, R., MODOLELL, M., WELTZIEN, H.U. & MUNDER, P.G. (1979). Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts. Immunobiology, 156, 498-508.
4. ARNOLD, B., REUTHER, R. & WELTZIEN, H.U. (1978). Distribution and metabolism of synthetic alkyl analogs of lysophosphatidylcholine in mice. Biochim. Biophys. Acta., 530, 47-55.
5. 3. Int. J. Immunopharmacol., 13, 385-392.
6. BEN-NUN, A., WERKERLE, H. & COHEN, I.R. (1981). The rapid isolation of clonable antigen specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol., 11, 195-199.
7. 3. Lipids, 22, 967-969.
8. BOGGS, K., ROCK, C.O. & JACKOWSKI, S. (1998). The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine. Biochim. Biophys. Acta., 1389, 1-12.
9. BRUNNER, T., MOGIL, R.J., LAFACE, D., YOO, N.J., A. MAHBOUBU, A., ECHEVERRI, F., MARTIN, S.J., FORCE, W.R., LYNCH, D.H., WARE, C.F. & GREEN, D.R. (1995). Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature, 373, 441-444.
10. 2)-dihydrocyclosporin effects in clinical, functional and histological studies. J. Autoimmunity., 5, 199-211.
11. DHEIN, J., WALCZAK, H., BÄUMLER, C., DEBATIN, K.-M. & KRAMMER, P.H. (1995). Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 373, 438-441.
12. DIOMEDE, L., COLOTTA, F., PIOVANI, B., RE, F., MODEST, E.J., & SALMONA, M. (1993). Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine: a possible basis for its selective action. Int. J. Cancer, 53, 124-130.
13. DIOMEDE, L., PIOVANI, B., RE, F., PRINCIPE, P., COLOTTA, F., MODEST, E.J. & SALMONA, M. (1994). The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. Int. J. Cancer, 57, 645-649.
14. ENGELHARDT, B., DIAMANTSTEIN, T. & WERKERLE, H. (1989). Immunotherapy of experimental autoimmune encephalomyelitis (EAE): Differential effect of anti-II.-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun., 2, 61-73.
15. FRIESEN, C., HERR, I., KRAMMER, P.H. & DEBATIN, K.-M. (1996). Involvement of CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med., 2, 574-577.
16. 2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid I-O?-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Mol. Pharmacol., 53, 602-612.
17. GAMEN, S., ANEL, A., LASIERRA, P., ALAVA, M.A., MARITINEZ-LORENZO, M.J., PINEIRO, A. & NAVAL, J. (1997). Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett., 417, 360-364.
18. GAVRIELI, Y., SHERMAN, Y. & BEN-SASSON, S.A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol., 119, 493-501.
19. GLASSER, L., DALTON, W.S., FIEDERLEIN, R.L., COOK, P., POWIS, G. & VOGLER, W.R. (1996). Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipids. Exp. Hematol., 24, 253-257.
20. HOULIHAN, W., LOHMEYER, M., WORKMAN, H. & CHEON, S.H. (1995). Phospholipid antitumor agents. Med. Res. Rev., 15, 157-223.
21. JU, S.-T., PANKA, D.J., CUT, H., ETTINGER, R., EL-KHATIB, M., SHERR, D.H., STANGER, B.Z. & MARSHAK-ROTHSTEIN, A. (1995). Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature, 373, 444-448.
22. KLEIN-FRANKE, A. &MUNDER, P.G. (1992). Alkyllysophospholipid prevents induction of experimental allergic encephalomyclitis. J. Autoimmunity, 5, 83-91.
23. KOENIGSMANN, M.P., NOTTER, M., KNAUF, W.U., PAPADIMITRIOU, C.A., OBERBERG, D., REUFI, B., MÜCKE, C., Thiel, E. & BERDEL, W.E. (1996). Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. Bone Marrow Transplant, 18, 549-557.
24. KONSTANTINOV, S.M., EIBL, II. & and BERGER, M.R. (1998). Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemother. Pharmacol., 41, 210-216.
25. KOVARIK, J., CHABANNES, D. & BOREL, J.F. (1995). Immunoregulation and drug treatment in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Int. J. Immunopharmacol., 17, 255-263.
26. KROEMER, G., ZAMZAMI, N. & SUSIN, S.A. (1997). Mitochondrial control of apoptosis. Immunol. Today, 18, 44-51.
27. LILES, W.C., KIENER, P.A., LEDBETTER, J.A., ARUFFO, A. & KLEBANOFF, S.J. (1996). Differential expression of Fas(CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med., 184, 429-440.
28. LOHMEYER, M. & BITTMAN, R. (1994). Antitumor ether lipids and alkylphosphocholines. Drugs Future, 19, 1021-1037.
29. LYNCH, D.H., RAMSDELL, F. & ALDERSON, M.R. (1995). Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today, 16, 569-574.
30. MARCHETTI, P., CASTEDO, M., SUSIN, S.A., ZAMZAMI, N., HIRSCH, T., MACHO, A., HAEFFNER, A., HIRSCH, F., GEUSKENS, M. & KROEMER, G. (1996). Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med., 184, 1155-1160.
31. MOLLINEDO, F., BURGALETA, C., VELASCO, G., ARROYO, A.G., ACEVEDO, A. & BARASOAIN, I. (1992). Enhancement of human neutrophil functions by a monoclonal antibody directed against a 19-kDa antigen. J. Immunol., 149, 323-330.
32. 1. Cancer Res., 57, 1320-1328.
33. MOLLINEDO, F., GAJATE, C. & MODOLELL, M. (1994). The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells. Biochem. J., 302, 325-329.
34. 3. Biochem. Biophys. Res. Commun., 192, 603-609.
35. MOLLINEDO, F., SANTOS-BENETT, A.M. & GAJATE, C. (1998). The human leukemia cell line HL-60 as a cell culture model to study neutrophil functions and inflammatory cell responses. In Animal Cell Culture Techniques. ed. Clynes, M. pp. 264-297. Heidelberg, Germany: Springer-Verlag.
36. MUNDER, P.G. & WESTPHAL, O. (1990). Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol., 49, 206-235.
37. NAGATA, S. (1997). Apoptosis by death factor. Cell, 88, 355-365.
38. NICOLETTI, I., MIGLIORATI, G., PAGLIACCI, M.C. & RICCARDI, C. (1991). A rapid simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Meth., 139, 271-280.
39. O'CONNELL, J., O'SULLIVAN, G.C., COLLINS, J.K. & SHANAHAN, F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184, 1075-1082.
40. ORMEROD, M.G., COLLINS, M.K.L., RODRIGUEZ-TARDUCHY, G. & ROBERTSON, D. (1992). Apoptosis in interleukin-3-dependent hemopoietic cells. Quantification by two cytometric methods. J. Immunol. Meth., 153, 57-65.
41. OSBORNE, B.A. (1996). Apoptosis and the maintenance of homeostasis in the immune system. Curr. Opin. Immunol., 8, 245-254.
42. PARIJS, L.V., BIUCKIANS, A. & ABBAS, A.K. (1998). Functional roles of Fas and Bcl-2-regulated apoptosis in T lymphocytes. J. Immunol., 160, 2065-2071.
43. PEREZ-SALA, D., COLLADO-ESCOBAR, D. & MOLLINEDO, F. (1995). Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J. Biol. Chem., 270, 6235-6242.
44. PETIT, P.X., LECOEUR, H., ZORN, E., DAUGUET, C., MIGNOTTE, B. & GOUGEON, M.L. (1995). Alterations of mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J. Cell. Biol., 130, 157-167.
45. PETIT, P.X., O'CONNOR, J.E., GRUNWALD, D. & BROWN, S.C. (1990). Analysis of the membrane potential of rat- and mouse-liver mitochondria by flow cytometry and possible applications. Eur. J. Biochem., 194, 389-397.
46. PLANTING, A.S., STOTER, G. & VERWEI, J. (1993). Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer, 29A, 518-519.
47. SATOII, J., SAKAI, K., ENDOII, M., KOIKE, F., KUNISHITA, T., NAMIKAWA, T., YAMAMURA, T. & TABIRA, T. (1987). Experimental allergic encephalomyelitis mediated by murine encephalitogenic T-cell lines specific for myelin proteolipid apoprotein. J. Immunol., 138, 179-184.
48. UNGER, C. & EIBL, H. (1991). Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug. Lipids, 26, 1412-1417.
49. UNGER, C., SINDERMANN, H., PEUKERT, M., HILGARD, P., ENGEL, J. & EIBL, H. (1992). Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog. Exp. Tumor Res., 34, 153-159.
50. VOGLER, W.R., BERDEL, W.E., GELLER, R.B., BROCHSTEIN, J.A., BEVERIDGE, R.A., DALTON, W.S., MILLER, K.B. & LAZARUS, H.M. (1996). A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv. Exp. Med. Biol., 416, 389-396.
51. VON MEHREN, M., GIANTONIO, B.J., MCALEER, C., SCHILDER, R., McPHILLlPS, J. & O'DWYER, P.J. (1995). Phase I trial of ilmofosine as a 24 h infusion weekly. Invest. New Drugs, 13, 205-210.
52. WINKELMANN, M., EBELING, K., STROHMEYER, G., HOTTENROTT, G., MECHL, Z., BERGES, W., SCHOLTEN, T., WESTERHAUSEN, M., SCHLIMOK, G. & STERZ, R. (1992). Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J. Cancer Res. Clin. Oncol., 118, 405-407.
53. 3 synergistically enhances the merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells. Bone Marrow Transplant, 19, 113-119.
54. ZAMVIL, S., NELSON, P., TROTTER, J., MITCHELL, D., KNBLER, R., FRITZ, R. & STEINMAN, L. (1985). T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyclination. Nature, 317, 355-358.
55. ZAMZAMI, N., MARCHETTI, P., CASTEDO, M., ZANIN, C., VAYSSIERE, J.L., PETIT, P.X. & KROEMER, G. (1995). Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med., 181, 1661-1672.